eFFECTOR Therapeutics Inc (OTCPK:EFTR)

$ 0.0002 0 (0%) Market Cap: 1,000.00 Enterprise Value: -5.13 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

eFFECTOR Therapeutics Inc R&D Day Transcript
Jan 24, 2024
eFFECTOR Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
eFFECTOR Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
eFFECTOR Therapeutics Inc Provides Positive Clinical Data Update for Zotatifin and General Corporate Update Call Transcript
Jan 05, 2023
eFFECTOR Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 15, 2022
eFFECTOR Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
eFFECTOR Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
eFFECTOR Therapeutics Inc Update on Expanded Development of Zotatifin - Corporate Call Transcript
Jun 05, 2022
eFFECTOR Therapeutics Inc Provides Pipeline and Business Updates - Conference Call Transcript
Jan 24, 2022

eFFECTOR Therapeutics Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 10:00PM GMT

Release Date Price: $12.35 (+0.80%)

Transcript 10-Q8-K

Judah Frommer

Credit Suisse - Analyst

Good afternoon, everyone. I'm Judah Frommer. I'm one of the SMID-cap biotech analysts here at Credit Suisse. And for this session, we're very happy to have the team from eFFECTOR here: Steve, Mike, and Doug.

So maybe if we just jump right in. We thought we could start with a background question on the platform and the origin story for -- how did you land on the eIF4F translation complex? And how should we think about the optionality available for potential therapeutic mechanisms?

Questions & Answers

Steve Worland

eFFECTOR Therapeutics, Inc. - President & CEO

Yeah. Thanks, Judah. Thanks for the invitation. It's great to be here. I mean, I'll start with that. And then -- a lot of other people join in.

So I think the idea with the translational complex was, one, recognizing where it sits in cell signaling. So it's downstream of the RAS and the PI3K pathways, and it's actually a point of convergence of those two pathways, one of the very early points in signaling where the two pathways

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.